A look back at the week's top stories.
Essentially no safe levels of toxic ‘forever chemicals’ found in many US water systems.
Results suggest the potential of this oral therapy to address the unmet clinical need for long-term medical treatment for endometriosis.
Evofem Biosciences, Inc. recently announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial, which investigated the ability of a contraceptive gel consisting of lactic acid, citric acid, and potassium bitartrate (Phexxi; Evofem) to prevent pregnancy.
Vaginal yeast infections were successfully treated with berberine, a biologically active herbal alkaloid, according to a study published in Frontiers in Pharmacology.
Using National Inpatient Sample data from a nearly 2 decade period, investigators detail the increased risk of cardiovascular complications among women with PCOS during delivery hospitalizations and predictors of this increased risk.
New research suggests cumulative exposure to PFAS could increase risk of incident hypertension by 71% among midlife women.